Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for DHR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DHR and 80,000+ other tickers.
See exactly how DHR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DHR and 80,000+ other tickers.
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics…
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Danaher (DHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
There's reason to believe the stock can stage a comeback after its worst day in two decades.
Andra AP fonden raised its holdings in shares of Danaher Corporation (NYSE: DHR) by 648.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 76,642 shares of the conglomerate's stock after buying an additional 66,405 shares during the period. Andra AP fonden's holdings
DHR beats Q2 estimates as Life Sciences posts its strongest quarter in years, prompting the company to raise its 2026 adjusted EPS outlook.
Danaher Corporation delivered Q2 revenue of $6.3B (+5.5% y/y), beating estimates and showing segment growth across Biotechnology, Diagnostics, and Life Sciences. Gross margins declined due to higher cost of sales, but operating margins improved significantly on tight SG&A control and DBS-driven productivity. Management raised full-year EPS guidance slightly, but projected low single-digit revenue growth and a slow recovery, disappointing investors and triggering a 14% share price drop.